![](/img/cover-not-exists.png)
382TiPCONTESSA TRIO: A multinational, multicenter, phase II study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with her2- metastatic breast cancer (MBC)
Tolaney, S M, Blum, J L, Bondarenko, I, Chan, A, DaCosta, N, Feng, Y -H, Izarzugaza, Y, Kim, S -B, Liu, M -C, Oliveira, M, Ow, S G W, Pavic, M, Peréz Lopéz, M E, Rugo, H S, Schwartzberg, L, Stradella,Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz242.077
Date:
October, 2019
File:
PDF, 96 KB
2019